Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | BAX | Q07812 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103797 | 0.90 | — | — | |
| SCHEMBL7129361 | 0.87 | LTA4H (0.43) | LTA4HTSHRNR1H2BAXCA1 | |
| SCHEMBL28032088 | 0.87 | LTA4H (0.43) | LTA4HTSHRNR1H2BAXCA1 | |
| Diphenylether SCHEMBL725398 | 0.82 | LTA4H (0.75) | LTA4HTSHRNR1H2BAXCA1 | |
| SCHEMBL14477632 | 0.82 | MEN1 (0.33) | CA1CA2CA9 | |
| SCHEMBL25661898 | 0.81 | MMP3 (0.44) | CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL819908 | 0.81 | MMP3 (0.44) | CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL25661896 | 0.81 | MMP3 (0.44) | CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL25661900 | 0.81 | MMP3 (0.44) | CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL449851 | 0.80 | LTA4H (0.63) | LTA4HTSHRNR1H2BAXCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2018-07-12 | — | — | US | disclosed |
| US-20180037583-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS LLC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-12-21 | — | — | US | disclosed |
| US-9840509-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2017-12-12 | — | — | US | disclosed |
| US-9795605-B2 | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors | PHARMACYCLICS LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | PHARMACYCLICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9637487-B2 | Purinone compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-9598425-B2 | Method for preparing Ibrutinib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-21 | — | — | US | disclosed |
| US-9540385-B2 | Pyrrolopyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160375026-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-20120184013-A1 | Inhibitors of BMX non-receptor tyrosine kinase | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | PHARMACYCLICS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LTA4H 4435/4885TSHR 3200/4885NR1H2 4636/4885 |
| US-20180037583-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | LTA4H 1886/4885TSHR 3511/4885NR1H2 3981/4885 |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LTA4H 4435/4885TSHR 3200/4885NR1H2 4636/4885 |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | BLK, DCK, LTK | LTA4H 2845/4885TSHR 2700/4885NR1H2 3581/4885 |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BTK, ABL1, JAK1 | LTA4H 2817/4885TSHR 1560/4885NR1H2 3820/4885 |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | LTA4H 3308/4885TSHR 2102/4885NR1H2 4540/4885 |
| US-20160375026-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, ZAP70 | LTA4H 2715/4885TSHR 2964/4885NR1H2 4428/4885 |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LTA4H 4435/4885TSHR 3200/4885NR1H2 4636/4885 |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | LTA4H 1313/4885TSHR 3088/4885NR1H2 3701/4885 |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LTA4H 4435/4885TSHR 3200/4885NR1H2 4636/4885 |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LTA4H 4435/4885TSHR 3200/4885NR1H2 4636/4885 |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | LTA4H 3308/4885TSHR 2102/4885NR1H2 4540/4885 |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LTA4H 4435/4885TSHR 3200/4885NR1H2 4636/4885 |
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | BTK, ABL1, LYN | LTA4H 3308/4885TSHR 2102/4885NR1H2 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.